Table of Content

1. VISTA As Emerging Immune Checkpoint
1.1 What Is VISTA Inhibition?
1.2 Structure & Biology Of VISTA Protein
1.3 Mechanism Of Action Of VISTA Inhibitors


2. VISTA As Inhibitory & Costimulatory Checkpoint
2.1 VISTA As Inhibitory Immune Checkpoint
2.2 VISTA As Costimulatory Checkpoint
2.3 VISTA Inhibition v/s Conventional Immune Checkpoint Inhibitors


3. Significance Of VISTA In Disease Progressiopn & Cure
3.1 Role Of VlSTA In Facilitating Cancer Progression
3.2 VISTA As Potential Cancer Biomarker
3.3 VISTA As Therapeutic Target In Autoimmune Diseases


4. Global VISTA Inhibitors Market & Clinical Development Outlook
4.1 Current Scenario
4.2 Future Opportunities


5. VISTA Targeted Therapies Trends & Clinical Innovation By Indication
5.1 Solid Cancers
5.2 Hematological Cancers
5.3 Autoimmune & Inflammatory Disorders


6. VISTA Targeted Therapies Trends & Clinical Innovation By Region
6.1 US
6.2 Europe
6.3 India
6.4 Australia


7. Global VISTA Inhibitors Clinical Trials Overview
7.1 By Country
7.2 By Indication
7.3 By Organization
7.4 By Phase


8. Global VISTA Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase
8.1 Preclinical
8.2 Phase I
8.3 Phase I/II
8.4 Phase III


9. Global VISTA Inhibitors Market Dynamics
9.1 Market Drivers
9.2 Market Challenges


10. Competitive Landscape
10.1 Aurigene Discovery Technologies
10.2 Curis
10.3 Hummingbird Bioscience
10.4 Kineta
10.5 PharmAbcine
10.6 Sensei Biotherapeutics



List of Figures

Figure 1-1: VISTA Protein - Structure
Figure 1-2: VISTA - Binding Partners
Figure 1-3: VISTA Inhibition - Basic Mechanism

Figure 2-1: VISTA – Role In Cancer Immunotherapy
Figure 2-2: VISTA – Role In Autoimmune Diseases
Figure 2-3: VISTA Inhibition - Edge Over Conventional Checkpoint Inhibition

Figure 3-1: VISTA Interaction With Immune Cells
Figure 3-2: VISTA - Mechanisms Of Immune Suppression
Figure 3-3: Dual Role Of VISTA In Cancer
Figure 3-4: VISTA As Predictive Biomarker
Figure 3-5: Autoimmune Diseases - VISTA Agonism

Figure 4-1: Future Market Opportunities

Figure 5-1: Solid Tumors – VISTA Role In Tumor Immune Evasion
Figure 5-2: SNS-101-2-1 Phase 1/2 (NCT05864144) Study – Initiation & Completion Year
Figure 5-3: HMBD-002-V4C26-01 Phase 1/2 (NCT05082610) Study – Initiation & Completion Year
Figure 5-4: Hematological Cancers - Mechanisms Of Immune Evasion By VISTA
Figure 5-5: Autoimmune & Inflammatory Disorders - VISTA As Ligand On APCs
Figure 5-6: Autoimmune & Inflammatory Disorders - VISTA As Receptor On T Cells
Figure 5-7: Kings College London & Dartmouth College VISTA Patent – Grant & Expiration Year

Figure 6-1: MarkV-01/KEYNOTE-E80 Phase 1 (NCT05957081) Study – Initiation & Completion Year

Figure 7-1: Global – Number Of VISTA Inhibitors In Clinical Trials By Country, 2025
Figure 7-2: Global – Number Of VISTA Inhibitors In Clinical Trials By Indication, 2025
Figure 7-3: Global – Number Of VISTA Inhibitors In Clinical Trials By Organization, 2025
Figure 7-4: Global – Number Of VISTA Inhibitors In Clinical Trials By Phase, 2025

Figure 9-1: Market Drivers & Opportunities
Figure 9-2: Market Challenges & Restraints
 

List of Tables

Table 5-1: VISTA – Role In Autoimmune & Inflammatory Disorders

Table 6-1: US – Ongoing Clinical Trials for VISTA Inhibitors